399 citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- Rice UniversityUS17 papers
- The University of Texas Health Science Center at HoustonUS17 papers
- The University of Texas at AustinUS13 papers
- Harvard UniversityUS12 papers
- Baylor College of MedicineUS10 papers
- The University of Texas Southwestern Medical CenterUS9 papers
- University of PennsylvaniaUS8 papers
- Massachusetts General HospitalUS7 papers
- Stanford UniversityUS7 papers
- Technical University of MunichDE7 papers
- University of Alabama at BirminghamUS7 papers
- University of North Carolina at Chapel HillUS7 papers
5 papers · 2 filters
Optimal Bayesian hierarchical model to accelerate the development of tissue-agnostic drugs and basket trials
Liyun Jiang, Lei Nie, Fangrong Yan +1
Tissue-agnostic trials enroll patients based on their genetic biomarkers, not tumor type, in an attempt to determine if a new drug can successfully treat disease conditions based o…
A Note on Bayesian Modeling Specification of Censored Data in JAGS
Xinyue Qi, Shouhao Zhou, Martyn Plummer
Just Another Gibbs Sampling (JAGS) is a convenient tool to draw posterior samples using Markov Chain Monte Carlo for Bayesian modeling. However, the built-in function dinterval() t…
A Framework for Mediation Analysis with Multiple Exposures, Multivariate Mediators, and Non-Linear Response Models
James P. Long, Ehsan Irajizad, James D. Doecke +2
Mediation analysis seeks to identify and quantify the paths by which an exposure affects an outcome. Intermediate variables which are effected by the exposure and which effect the…
Elastic Priors to Dynamically Borrow Information from Historical Data in Clinical Trials
Liyun Jiang, Lei Nie, Ying Yuan
Use of historical data and real-world evidence holds great potential to improve the efficiency of clinical trials. One major challenge is how to effectively borrow information from…
Design of phase III trials with long-term survival outcomes based on short-term binary results
Marta Bofill Roig, Yu Shen, Guadalupe Gómez Melis
Pathologic complete response (pCR) is a common primary endpoint for a phase II trial or even accelerated approval of neoadjuvant cancer therapy. If granted, a two-arm confirmatory…